TIAA CREF Individual & Institutional Services LLC boosted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 41,526 shares of the company’s stock after purchasing an additional 1,922 shares during the period. TIAA CREF Individual & Institutional Services LLC’s holdings in Eli Lilly and Company were worth $48,049,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of LLY. TD Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 10.6% during the 3rd quarter. TD Capital Management LLC now owns 73 shares of the company’s stock valued at $85,000 after buying an additional 7 shares in the last quarter. FCA Corp TX boosted its stake in Eli Lilly and Company by 1.9% in the third quarter. FCA Corp TX now owns 371 shares of the company’s stock worth $429,000 after buying an additional 7 shares in the last quarter. Integrity Financial Corp WA grew its position in Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after acquiring an additional 8 shares during the last quarter. LCM Capital Management Inc raised its stake in shares of Eli Lilly and Company by 3.3% during the third quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock worth $293,000 after acquiring an additional 8 shares in the last quarter. Finally, Smith Shellnut Wilson LLC ADV raised its stake in shares of Eli Lilly and Company by 4.1% during the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock worth $235,000 after acquiring an additional 8 shares in the last quarter. 82.53% of the stock is owned by institutional investors.
Key Stories Impacting Eli Lilly and Company
Here are a few of the latest stories about LLY:
- Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, potentially broadening the drug’s use and commercial opportunity. Article: Health Canada approves Lilly’s Mounjaro
- Positive Sentiment: Lilly is expanding its oncology research through the acquisition of Calytrix Bio and a multi-target collaboration with Stipple Bio. The deals add programs and research capabilities, though their financial impact will depend on development progress. Article: Eli Lilly expands its oncology research platform
- Neutral Sentiment: Recent updates cover studies of brenipatide, LY3839056, tirzepatide, and the cost of Alzheimer’s care. The reports describe study activity or updates, but the supplied information does not identify new efficacy results, so their near-term effect on valuation is unclear. Article: Lilly tests brenipatide in a depression study
Analyst Ratings Changes
A number of brokerages have recently issued reports on LLY. Jefferies Financial Group upped their price objective on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Bank of America reiterated a “buy” rating and issued a $1,497.00 target price on shares of Eli Lilly and Company in a research report on Friday, October 30th. Argus raised their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday, October 30th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, October 20th. Finally, Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price for the company in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,422.00.
Read Our Latest Stock Report on Eli Lilly and Company
Insider Activity
In other news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $1,346.40 on Friday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,475.25. The company has a market capitalization of $1.27 trillion, a price-to-earnings ratio of 43.70, a price-to-earnings-growth ratio of 1.71 and a beta of 0.40. The company’s 50-day moving average is $1,268.06 and its 200 day moving average is $1,119.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. Eli Lilly and Company’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period last year, the company earned $7.02 EPS. Sell-side analysts expect that Eli Lilly and Company will post 35.72 EPS for the current fiscal year.
Eli Lilly and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Recommended Stories
- Five stocks we like better than Eli Lilly and Company
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
